2010
DOI: 10.1016/j.ijantimicag.2010.03.006
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: A comparative study was performed between the trypanocidal efficacy of and associated immune response to benznidazole and posaconazole in a murine model of Chagas disease. Both drugs led to 100% survival, suppression of parasitaemia and reduction of specific anti-Trypanosoma cruzi antibodies following chronic infection. All posaconazole-treated animals had negative haemocultures at 54 days post infection, whilst 50% of those treated with benznidazole had positive results. Although both drugs were effective in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
30
0
11

Year Published

2011
2011
2016
2016

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 59 publications
(43 citation statements)
references
References 15 publications
2
30
0
11
Order By: Relevance
“…In subsequent studies, a dose of 20 mg/kg q.d. was typically used to characterize the in vivo anti-T. cruzi activity of posaconazole (9,17). In our experiments, such a regimen translated into a maximum plasma concentration (C max, total ) of 5.9 M and an AUC 0 -24, total of 97 h · M at steady state.…”
Section: Resultsmentioning
confidence: 99%
“…In subsequent studies, a dose of 20 mg/kg q.d. was typically used to characterize the in vivo anti-T. cruzi activity of posaconazole (9,17). In our experiments, such a regimen translated into a maximum plasma concentration (C max, total ) of 5.9 M and an AUC 0 -24, total of 97 h · M at steady state.…”
Section: Resultsmentioning
confidence: 99%
“…Ultimately, vaccine development is a stepwise process and using the acute model for screening vaccine candidates can be used as an effective in vivo model to determine whether a vaccine would stimulate a sufficient immune response to control parasitemia, and is frequently used in drug efficacy testing. [53][54][55] Additionally, while a concerted effort has been made to select mouse models that closely mimic human disease, the Tcell response is not directly translatable between the two species. While we predict that our findings of immunogenicity and Figure 6.…”
Section: Discussionmentioning
confidence: 99%
“…As ergosterol is the predominant sterol of the parasite membrane [11], several inhibitors of ergosterol synthesis, initially developed for the treatment of invasive fungal infections, have appeared as alternatives. One of these inhibitors, namely posaconazole (POS), a triazole derivative that potentially inhibits the course of T. cruzi infection in mice, is presently undergoing clinical trials [4,12]. Another compound, AmBisome ® (AMB) (a liposomal formulation of the macrolide polyene amphotericin B), displays a high affinity for ergosterol and is also a current and potent treatment of invasive fungal infections as well as visceral leishmaniasis.…”
Section: Introductionmentioning
confidence: 99%